In vitro selective elimination of HIV-infected cells from peripheral blood in AIDS patients by the immunotoxin DAB389CD4

AIDS

Volumn 12, Issue 8, 1998, Pages 859-863

  Martín Serrano, Juan ^a   Folgueira, Lola ^a   Laín De Lera, Teresa ^a   Pedraza, Maria Antonia ^a   Lemichez, Emmanuel ^b   Sánchez Palomino, Sonsoles ^a   Noriega, Antonio R ^a   Boquet, Patrice ^b   Alcamí, José ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b INSERM   (France)

Author keywords

Antiviral therapy; CD4; Eradication; gp120; Immunotoxin

Indexed keywords

CD4 ANTIGEN; IMMUNOTOXIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CLINICAL ARTICLE; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; LYMPHOCYTE PROLIFERATION; MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIGENS, CD4; CELL SURVIVAL; CELLS, CULTURED; DIPHTHERIA TOXIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV; HIV CORE PROTEIN P24; HUMANS; IMMUNOTOXINS; LEUKOCYTES, MONONUCLEAR; PHENOTYPE; PROVIRUSES; RECOMBINANT FUSION PROTEINS; RNA, VIRAL; VIRUS REPLICATION;

EID: 0032574892     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199808000-00007     Document Type: Article

References (22)

1. Pantaleo G: How immune-based interventions can change HIV therapy. Nature Med 1997, 3:483-486.
2. Tamalet C, Lafeuillade A, Fantini J, Poggi C, Yahi N: Quantification of HIV-1 viral load in lymphoid and blood cells: assessment during four-drug combination therapy. AIDS 1997, 11:895-901.
3. Stellbrink H-J, van Lunzen J, Hufert FT, et al.: Asymptomatic HIV infection is characterized by rapid turnover of HIV RNA in plasma and lymph nodes but not of latently infected lymph-node CD4+ T cells. AIDS 1997, 11:1103-1110.
4. Cavert W, Notermans DW, Starkus K, et al.: Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997, 276:960-964.
5. Thrush CR, Lark LR, Clinchy BC, Vitetta ES: Immunotoxins: an update. Annu Rev Immunol 1996, 14:49-71.
6. Aullo P, Alcamí J, Popoff MR, Klatzman DR, Murphy JR, Boquet P: A recombinant diphtheria toxin related human CD4 fusion protein specifically kills HIV-infected cells which express gp120 but selects fusion toxin resistant cells which carry HIV. EMBO J 1995, 11:575-583.
7. Ou CY, Ting Y, Greer CE, et al.: DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells. Science 1988, 238:295-297.
8. Folks TM, Powell D, Lightfoote M, et al.: Biological and biochemical characterization of a cloned Leu-3 cell surviving infection with the acquired immune deficiency syndrome retrovirus. J Exp Med 1986, 164:280-290.
9. Schwartz O, Virelizier J, Montagnier L, Hazan U: A microtransfection method using the luciferase-encoding reporter gene for the assay of human immuno-deficiency virus LTR promoter activity. Gene 1990, 88:197-205.
10. Alcamí J, Laín de Lera T, Folgueira L, et al.: Absolute dependence on KB responsive elements for initiation and Tatmediated amplification of HIV transcription in blood CD4 T lymphocytes. EMBO J 1995, 14:1552-1560.
11. Kozak SL, Platt EJ, Madani N, Ferro FE, Peden K, Kabat D: CD4, CXCR4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. J Virol 1997, 71:873-882.
12. Platt EJ, Madani N, Kozak SL, Kabat D: Infectious properties of human immunodeficiency virus type 1 mutants with distinct affinities for the CD4 receptor. J Virol 1997, 71:883-890.
13. Sanchez C, Xiaoyuan X, Cherman JC, Hirsch I: Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals. J Virol 1997, 71:2233-2240.
14. Gotlieb SL, Cilleaudeau P, Johnson R, et al.: Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med 1995, 1:442-447.
15. Finberg RW, Wahl SM, Allen JB, et al.: Selective elimination of HIV-infected cells with an interleukin-2 receptor-specific cytotoxin. Science 1991, 252:1703-1705.
16. Zhang LJ, Waters CA, Poisson LR, Estis LF, Crumpacker CS: The interleukin-2 fusion protein, DAB389IL-2, inhibits the development of infectious virus in human immunodeficiency virus type 1-infected human peripheral blood mononuclear cells. J Infect Dis 1997, 175:790-794.
17. Anderson JJ, O'Neill A, Woodworth T, Haddad J, Sewell KL, Moreland LW: Health status response of rheumatoid arthritis to treatment with DAB486IL-2. Arthritis Care Res 1996, 9:112-119.
18. LeMaistre CF, Meneghetti C, Rosenblum M, et al.: Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematological malignancies expressing the IL-2 receptor. Blood 1992, 79:2547-2554.
19. LeMaistre CF, Craig FE, Meneghetti C, et al.: Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers. Cancer Res 1993, 53:3930-3934.
20. Davey RT, Boenning CM, Herpin BR, et al.: Use of recombinant soluble CD4 Pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with human immunodeficiency virus. J Infect Dis 1994, 170:1180-1188.
21. Ramachandran RV, Katzenstein DA, Wood R, Batts DH, Merigan TC: Failure of short-term CD4-PE40 infusions to reduce virus load in human immunodeficiency virus-infected persons. J Infect Dis 1994, 170:1009-1013.
22. Hwang J, Fitzgerald DJ, Adhya S, Pastan I: Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell 1987, 48:129-136.